Explore the latest news from Khondrion and its team.
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the...
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces its...
Study will examine the pharmacokinetics, safety and efficacy of sonlicromanol, one of the most advanced disease-modifying drug candidates in...
NIJMEGEN, the Netherlands – 6 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...
Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...
How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...
When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...
How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...
When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...